Hinge Health expands into migraine care with FDA-cleared wearable
Migraine affects around one in six Americans, with women experiencing it at roughly twice the rate of men.
Hinge Health has launched a new Migraine Care Program, combining its newly-FDA-cleared Enso® device with AI-driven trigger tracking and clinician-led prevention - marking a significant expansion beyond its core musculoskeletal (MSK) offering.
The move targets one of the most common and disabling neurological conditions. Migraine affects around one in six Americans, with women experiencing it at roughly twice the rate of men. It also frequently overlaps with MSK conditions, with around 75% of people reporting both - a link Hinge Health is now explicitly building into its care model.
“Migraine is one of the most disabling and widespread neurologic conditions, yet existing treatment options are insufficient,” said Dr. Jeffrey Krauss, Chief Medical Officer at Hinge Health.
“The FDA recently cleared our proprietary Enso device for the treatment of migraine, enabling us to deliver a first-of-its-kind care solution that combines groundbreaking technology with a full care team.”
Scaling a solution through employers
The programme centres on Enso, a wearable designed to deliver rapid, drug-free pain relief, alongside personalised insights to help users identify triggers across environmental, lifestyle and dietary factors. It also incorporates exercise therapy and behaviour change support aimed at reducing the frequency and severity of attacks over time.
The scale signal is notable. More than 125 clients - covering over two million people - have already adopted the Migraine Care Program, pointing to strong employer demand for solutions addressing a condition that drives more than $16,000 in annual healthcare costs per patient and an estimated $78 billion in lost productivity across the U.S. each year.
“We’re excited to introduce this Migraine Care Program especially because our employees consistently share positive experiences with Hinge Health’s offerings,” said Rachel Harrell, Manager of Benefits Strategy at Sodexo.
“We’re committed to expanding benefits that truly make a difference.”
Migraine sits at the intersection of neurology, chronic pain and women’s health - but it is increasingly being captured by scaled, generalist care platforms rather than women’s health-specific companies.
Hinge Health’s expansion reflects the broader shift: some of the largest opportunities in women’s health are being built outside the category itself - embedded into employer health platforms, chronic care models and mainstream digital health infrastructure.